Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 11, 2024
Reporting Period: Event date October 11, 2024
Business Context: The Company, an emerging growth company incorporated in Delaware, entered into a material definitive agreement to establish an "at-the-market" equity offering program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed relates to the potential capital raise:
- Maximum Offering Size: Up to $5,100,000 in aggregate offering price.
- Underwriting Commission: 3.0% of aggregate gross sales proceeds.
- Expense Reimbursement Cap: Up to $50,000 for specified expenses (including counsel fees) plus up to $7,500 for diligence bring-downs.
Material Changes
The filing reports the entry into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. This agreement allows the Company to issue and sell shares of common stock from time to time at its sole discretion. This represents a new mechanism for raising capital compared to prior periods, utilizing a registration statement on Form S-3 declared effective on October 10, 2024.
Guidance, Outlook, and Risks
Management Commentary: The Company is not obligated to sell any shares under the agreement. Sales will be made based on instructions from the Company, including price or size limits. The offering may be terminated by either the Company or the agent.
Risks and Contingencies:
- Dilution: Issuance of new shares will dilute existing shareholders.
- Market Conditions: Sales are subject to market conditions and the Company's discretion.
- Legal Liability: The Company has agreed to indemnify the agent against certain liabilities under the Securities Act and the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $5,100,000 worth of shares.
- Review the full text of the At The Market Offering Agreement (Exhibit 10.1) for specific termination rights and covenants.
- Confirm the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Check subsequent filings to determine if and when shares have actually been sold under this agreement.